U.S. Flow Cytometry Market Size To Reach $2.61 Billion By 2030

U.S. Flow Cytometry Market Growth & Trends 

The U.S. flow cytometry market size is anticipated to reach USD 2.61 billion by 2030 and is growing at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market for flow cytometry is expanding faster in the U.S. owing to increased cancer cases and other chronic illnesses. According to the American Cancer Society (ACS), there were roughly 9,270 cancer deaths among adolescents and young adults in the U.S. in 2019 who were between the ages of 15 and 39, and there were about 89,500 new cases of cancer diagnosed in 2020. These factors would drive market growth.

The COVID-19 pandemic had a positive effect on the market. For instance, in August 2020, research published in Springer discovered that flow cytometry analysis of peripheral blood mononuclear cell (PBMC) phenotype helped to predict the risk of COVID-19 clinical progression and indicated that improved antigen presentation and more effective adaptive immune responses are associated with recovery from COVID-19. The increasing frequency of infectious and chronic disorders, most notably the COVID-19 outbreak, has increased the need for technology for study and diagnosis, supporting the market's growth.

Furthermore, the U.S. has a robust healthcare infrastructure, significant healthcare spending, and widespread usage of highly advanced flow cytometry technologies. In addition, owing to research universities engaging in a wide range of research activities and having developed pharmaceutical enterprises, there is an enormous need for flow cytometry workflow for research purposes. This results from the U.S.'s substantial investment in healthcare, highly developed healthcare infrastructure, and widespread usage of cutting-edge flow cytometry technology.

 Request a free sample copy or view report summary: U.S. Flow Cytometry Market Report

U.S. Flow Cytometry Market Report Highlights

• Based on product, instrument dominated the market and accounted for 35.08% in 2023. Flow cytometry instruments are crucial in clinical diagnostics for applications such as immunophenotyping cells to monitor HIV/AIDS progression, detect minimal residual disease in leukemia, and assess immune cell function, which will fuel the segment growth

• In terms of technology, the cell-based segment dominated the market share in 2023. This technology involves analyzing cells based on their characteristics, such as size, complexity, and the presence of specific molecules. On the other hand, the bead-based segment is expected to grow at the fastest CAGR over the forecast period

• Based on application, the clinical segment held the largest market share in 2023. The industrial segment is expected to grow fastest over the forecast period

• In terms of end-use, the academic institute segment held the largest market share in 2023. Clinical testing labsare anticipated to witness the fastest growth over the forecast period

• The U.S. is the major dominating country in the market due to the surging incidence rate of diseases such as cancer and HIV amongst the population in this country, which is boosting the demand for U.S. flow cytometry market

• In January 2024, Sony Biotechnology launched the EC800, a highly versatile flow cytometry analyzer. This innovative device caters to various applications, such as particle sizing, immunophenotyping, cell viability, absolute cell counting, and apoptosis detection, among others. The EC800 offers cost-effective solutions suitablefor diverse research and diagnostic needs.

U.S. Flow Cytometry Market Segmentation

Grand View Research has segmented the U.S. flow cytometry market based on product, technology, application, end-use, and region:

U.S. Flow Cytometry Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Cell Analyzers

• Cell Sorters

• Reagents & Consumables

• Software

• Accessories

• Services

U.S. Flow Cytometry Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Cell-based

• Bead-based

U.S. Flow Cytometry Application Outlook (Revenue, USD Million, 2018 - 2030)

• Research

• Pharmaceutical

  • Drug Discovery

  • In Vitro Toxicity

  • Stem Cell

• Apoptosis

• Cell Sorting

• Cell Cycle Analysis

• Immunology

• Cell Viability

• Industrial

• Clinical

• Cancer

• Organ Transplantation

• Immunodeficiency

• Hematology

• Autoimmune Disorders

U.S. Flow Cytometry End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Clinical Testing Labs

• Academic Institutes

• Commercial Organizations

• Biotechnology Companies

• Pharmaceutical Companies

• CROs   

• Hospitals

U.S. Flow Cytometry Regional Outlook (Revenue, USD Million, 2018 - 2030)

• West

• Midwest

• Northeast

• Southwest

• Southeast

List of Key Players in the U.S. Flow Cytometry Market

• Sysmex Corp

• Becton, Dickinson, and Company (B.D.)

• Danaher Corp

• Thermo Fisher Scientific, Inc.

• Agilent Technologies, Inc.

• Bio-Rad Laboratories, Inc.

• Sony Biotechnology, Inc.

• Beckman Coulter, Inc.

• Cytek Biosciences

• BioLegend, Inc.

• Enzo Biochem Inc.

• Cell Signaling Technology, Inc.

• NeoGenomics Laboratories

• Q2 Solutions (IQVIA)

• Elabscience Biotechnology Inc.

• Stratedigm, Inc.

• BioLegend, Inc.

• Union Biometrica, Inc.

• BennuBio Inc.

• ORLFO Technologies